Results 31 to 40 of about 2,487,415 (296)
Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
Thoracic Cancer, 2020 Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj +1 more source
Characterization of a Cisplatin-resistant HeLa subline and mechanisms of cisplatin-resistance.
Journal of Japan Society for Oral Tumors, 1990 ヒト口腔領域由来腫瘍細胞, UEDA, NAKATA, KANETSUKI, HSG, HSY, 子宮頸部由来HeLa, 外陰部由来A431の7種の培養細胞を用いてシスプラチンに対する感受性を検索した。腺癌細胞は扁平上皮癌細胞に比べてシスプラチンに対して高い感受性を示し, 唾液腺腺癌に化学療法が有用であると示唆された。また, 一方扁平上皮癌細胞は自然耐性を示した。シスプラチンに感受性の高い細胞は高い細胞内シスプラチン濃度を示し, シスプラチンの取り込みは殺細胞効果を反映すると考えられた。シスプラチン耐性のメカニズムを解明するためにHeLa細胞を用いてシスプラチン耐性細胞を分離した (HeLaDDP) 。同細胞はシスプラチン非存在下17ケ月間継代培養した後も約4.3倍の安定した耐性を発現していた ...
Furue, Miho +2 more
openaire +2 more sources
Metabolic vulnerability of cisplatin‐resistant cancers [PDF]
The EMBO Journal, 2018 Cisplatin is the most widely used chemotherapeutic agent, and resistance of neoplastic cells against this cytoxicant poses a major problem in clinical oncology. Here, we explored potential metabolic vulnerabilities of cisplatin-resistant non-small human cell lung cancer and ovarian cancer cell lines.
Florine Obrist +11 more
openaire +2 more sources
Frontiers in Pharmacology, 2017 Resistance to platinum-based chemotherapy is one of the most important reasons for treatment failure in advanced non-small cell lung cancer, but the underlying mechanism is extremely complex and unclear.
Aman Wang +7 more
doaj +1 more source
Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]
, 2010 The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp +7 more
core +1 more source
CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma. [PDF]
PLoS ONE, 2014 Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients.
Hsiao-Chi Tsai +3 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2020 Cisplatin [cis-diamminedichloroplatinum (II)] is a platinum-based anticancer drug widely used for the treatment of various cancers. It forms interstrand and intrastrand cross-linking with DNA and block DNA replication, resulting in apoptosis.
Takahiro Shimizu +2 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2019 Background Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene
Wei-Min Chang +5 more
doaj +1 more source
New precious metal compounds in cancer therapy [PDF]
, 2008 Includes abstract.Includes bibliographical references (leaves 139-160).Cisplatin is one of the most effective cancer medications currently available. However, it is seriously limited by patient toxicity and drug resistance.
Peters, Dean Douglas
core +1 more source
Alternative redox forms of ASNA-1 separate insulin signaling from tail-anchored protein targeting and cisplatin resistance in C. elegans [PDF]
, 2021 Cisplatin is a frontline cancer therapeutic, but intrinsic or acquired resistance is common. We previously showed that cisplatin sensitivity can be achieved by inactivation of ASNA-1/TRC40 in mammalian cancer cells and in Caenorhabditis elegans.
Kraish, Bashar, +22 more
core +1 more source